Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Applied Health Economics and Health Policy
Published in: Applied Health Economics and Health Policy 5/2013

Open Access 01-10-2013 | Original Research Article

Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment

Authors: A. Ramírez de Arellano, A. Coca, M. de la Figuera, C. Rubio-Terrés, D. Rubio-Rodríguez, A. Gracia, A. Boldeanu, J. Puig-Gilberte, E. Salas

Published in: Applied Health Economics and Health Policy | Issue 5/2013

Login to get access

Abstract

Background

A clinical–genetic function (Cardio inCode®) was generated using genetic variants associated with coronary heart disease (CHD), but not with classical CHD risk factors, to achieve a more precise estimation of the CHD risk of individuals by incorporating genetics into risk equations [Framingham and REGICOR (Registre Gironí del Cor)].

Objective

The objective of this study was to conduct an economic analysis of the CHD risk assessment with Cardio inCode®, which incorporates the patient’s genetic risk into the functions of REGICOR and Framingham, compared with the standard method (using only the functions).

Methods

A Markov model was developed with seven states of health (low CHD risk, moderate CHD risk, high CHD risk, CHD event, recurrent CHD, chronic CHD, and death). The reclassification of CHD risk derived from genetic information and transition probabilities between states was obtained from a validation study conducted in cohorts of REGICOR (Spain) and Framingham (USA). It was assumed that patients classified as at moderate risk by the standard method were the best candidates to test the risk reclassification with Cardio inCode®. The utilities and costs (€; year 2011 values) of Markov states were obtained from the literature and Spanish sources. The analysis was performed from the perspective of the Spanish National Health System, for a life expectancy of 82 years in Spain. An annual discount rate of 3.5 % for costs and benefits was applied.

Results

For a Cardio inCode® price of €400, the cost per QALY gained compared with the standard method [incremental cost-effectiveness ratio (ICER)] would be €12,969 and €21,385 in REGICOR and Framingham cohorts, respectively. The threshold price of Cardio inCode® to reach the ICER threshold generally accepted in Spain (€30,000/QALY) would range between €668 and €836. The greatest benefit occurred in the subgroup of patients with moderate–high risk, with a high-risk reclassification of 22.8 % and 12 % of patients and an ICER of €1,652/QALY and €5,884/QALY in the REGICOR and Framingham cohorts, respectively. Sensitivity analyses confirmed the stability of the study results.

Conclusions

Cardio inCode® is a cost-effective risk score option in CHD risk assessment compared with the standard method.
Literature
1.
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, for the Cuarto Grupo de Trabajo Conjunto de la Sociedad Europea de Cardiología y otras Sociedades sobre Prevención de la Enfermedad Cardiovascular en la Práctica Clínica, et al. Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Rev Esp Cardiol. 2008;61:e1–49.CrossRef
2.
3.
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423–6.PubMedCentralPubMedCrossRef
4.
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.PubMedCentralPubMedCrossRef
5.
De la Peña A. Epidemiología de la enfermedad cardiovascular y de sus factores de riesgo en España. In: Suárez C (Coord.) Protocolos de riesgo cardiovascular. Madrid: Sociedad Española de Medicina Interna; 2004. p. 15–24.
6.
Instituto Nacional de Estadística. Defunciones según la causa de muerte. Año 2009. Madrid: INE; 2012.
7.
Pyörälä K, de Backer G, Graham I, Pooloe-Wilson P, Word D. Prevention of coronary heart disease in clinical practice: recommendation of the task force of the European Society of Cardiology, European Atherosclerosis and European Society of Hypertension. Atherosclerosis. 1994;2:121–61.CrossRef
8.
Riesgo cardiovascular: Guía de actuación en Atención Primaria. Palma de Mallorca: Gerencia de Atención Primaria de Mallorca; 2006.
9.
Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framminghan study. Ann Intern Med. 1971;74:1–12.PubMedCrossRef
10.
Marrugat M, Vila J, Baena-Díez JM, Grau JM, Ramos R, Subirana I, et al. Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study. Rev Esp Cardiol. 2011;64:385–94.PubMedCrossRef
11.
Marrugat J, Solanas P, D’Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253–61.PubMedCrossRef
12.
Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol. 2007;60:476–85.PubMedCrossRef
13.
Lluís-Ganella C, Lucas G, Subirana I, Sentí M, Jiménez-Conde J, Marrugat J, et al. Efecto aditivo de diferentes variantes genéticas en el riesgo de cardiopatía isquémica. Rev Esp Cardiol. 2010;63:925–33.PubMedCrossRef
14.
Elosua R, Lluís C, Lucas G. Estudio del componente genético de la cardiopatía isquémica: de los estudios de ligamiento al genotipado integral del genoma. Rev Esp Cardiol. 2009;9(Suppl B):B24–38.
15.
Lluis-Ganella C, Subirana I, Lucas G, Tomás M, Muñoz D, Sentí M, et al. Predictive capacity of the Framingham coronary risk function improved by including a genetic score. Atherosclerosis. 2012;222:456–63.PubMedCentralPubMedCrossRef
16.
Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;2:210–5.CrossRef
17.
Erdmann J, Grosshennig A, Braund PS, Konig IR, Hengstenberg C, Hall AS, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet. 2009;41:280–2.PubMedCentralPubMedCrossRef
18.
Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–3.PubMedCrossRef
19.
Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334–41.PubMedCrossRef
20.
McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488–91.PubMedCentralPubMedCrossRef
21.
Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genome wide association analysis of coronary artery disease. N Engl J Med. 2007;357:443–53.PubMedCentralPubMedCrossRef
22.
Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, Hall AS, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009;41:283–5.PubMedCrossRef
23.
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.CrossRef
24.
25.
Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408–16.PubMedCentralPubMedCrossRef
26.
Rubio-Terrés C, Echevarría A. La herramienta clave: modelos de Markov. Pharmacoecon Spa Res Art. 2006;3(Suppl. 2):71–8.
27.
28.
29.
García-García C, Sanz G, Valle V, Molina L, Sala J, Subirana I, et al. Evolución de la mortalidad intrahospitalaria y el pronóstico a seis meses de los pacientes con un primer infarto agudo de miocardio. Cambios en la última década. Rev Esp Cardiol. 2010;63:1136–44.PubMedCrossRef
30.
Hurtado-Martínez J, Pinar-Bermúdez E, Teruel-Carrillo F, Gimeno-Blanes JR, Lacunza-Ruiz J, Valdesuso R, et al. Mortalidad a corto y largo plazo en mujeres con infarto de miocardio tratado con angioplastia primaria. Rev Esp Cardiol. 2006;59:1113–22.PubMedCrossRef
31.
Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess. 2008;12(21):iii, xi–xiii, 1–212.
32.
Ahumada M, Cabadés A, Valencia J, Cebrián J, Payá E, Morillas P, Investigadores del registro PRIMVAC, et al. El reinfarto como complicación del infarto agudo de miocardio. Datos del registro PRIMVAC. Rev Esp Cardiol. 2005;58:13–9.PubMedCrossRef
33.
Ara R, Pandor A, Stevens J, Rees A, Rafia R. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess. 2009;13(34):1–74, 75–118
34.
Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. New York: Oxford University Press; 1994.
35.
Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13:509–18.PubMedCrossRef
36.
Sicras A, Velasco S. González n, Rodríguez JL. Evaluación clínica y económica según el grado de riesgo cardiovascular en sujetos pertenecientes a un ámbito poblacional español. Med Clin (Barc). 2008;131:158–9.CrossRef
37.
Base de datos de costes sanitarios españoles. Versión 3.1. Madrid: Health Value; 2011.
38.
Ruiz I, Ramos JR, Hernández I. Variaciones en la prevención del riesgo cardiovascular: estudio poblacional. Gac Sanit. 2003;17:20–6.CrossRef
39.
Rubio-Terrés C, Cobo E, Sacristán JA, Prieto L, del Llano J, Badia X, Grupo ECOMED. Análisis de la incertidumbre en las evaluaciones económicas de intervenciones sanitarias. Med Clin (Barc). 2004;122:668–74.CrossRef
40.
Brigss A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
41.
Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología eficiente en España? Gac Sanit. 2002;16:334–43.PubMedCrossRef
42.
Kadambi A, Leipold RJ, Kansal AR, Sorensen S, Getsios D. Inclusion of compliance and persistence in economic models: past, present and future. Appl Health Econ Health Policy. 2012;10:365–79.PubMedCrossRef
43.
44.
Helin-Salmivaara A, Lavikainen P, Korhonen MJ, Halava H, Junnila SY, Kettunen R, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther. 2008;30:2228–40.PubMedCrossRef
45.
Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458–62.PubMedCrossRef
46.
Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manage Care. 1999;5:437–44.
47.
TreeAge Pro Healthcare Module 2009. Williamstown: TreeAge Software Inc.; 2009.
48.
Greiner W, Weiinen T, Nieuwenhuizen M, Oppe S, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4:222–31.PubMedCrossRef
49.
Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.PubMedCentralPubMedCrossRef
50.
Wee H-L, Machin D, Loke W-C, Li S-C, Cheung Y-B, Luo N, et al. Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health. 2007;10:256–65.PubMedCrossRef
51.
Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165–8.PubMedCrossRef
52.
Arkadianos I, Valdes AM, Marinos E, Florou A, Gill RD, Grimaldi KA. Improved weight management using genetic information to personalize a calorie controlled diet. Nutr J. 2007;18(6):29.CrossRef
53.
Ashley EA, Hershberger RE, Caleshu C, Ellinor PT, Garcia JG, Herrington DM, American Heart Association Advocacy Coordinating Committee, et al. Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2012;126:142–57.PubMedCentralPubMedCrossRef
Metadata
Title
Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment
Authors
A. Ramírez de Arellano
A. Coca
M. de la Figuera
C. Rubio-Terrés
D. Rubio-Rodríguez
A. Gracia
A. Boldeanu
J. Puig-Gilberte
E. Salas
Publication date
01-10-2013
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 5/2013
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-013-0053-x

Other articles of this Issue 5/2013

Applied Health Economics and Health Policy 5/2013 Go to the issue

Original Research Article

Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US

Original Research Article

Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany

Current Opinion

Generic Medicines: Solutions for a Sustainable Drug Market?

Original Research Article

Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis

Original Research Article

Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland

Systematic Review

Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing